Literature DB >> 22277139

Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension: a retrospective subgroup analysis of the Observational Study on Cognitive Function and SBP Reduction (OSCAR) study.

Robert J Petrella1, Evgeny Shlyakhto, Alexandra O Konradi, Jean-Pascal Berrou, Armand Sedefdjian, Atul Pathak.   

Abstract

The Observational Study on Cognitive Function and SBP Reduction (OSCAR) provided opportunities to examine the influence of eprosartan on trends in cognitive performance in a large population of patients with difficult-to-treat hypertension (DTTH). A total of 4649 patients diagnosed retrospectively with DTTH, defined as systolic/diastolic blood pressure (SBP/DBP) ≥140/90 mm Hg despite use of at least 3 antihypertensive drugs during the month preceding the baseline visit comprised the intention-to-treat (ITT) cohort. The patients were given eprosartan-based antihypertension therapy (EBT; 600 mg/d). Blood pressure and cognitive function parameters included significant (P<.001) differences for DTTH vs non-DTTH patients such as older age, body mass index, SBP and pulse pressure (PP), and lower Mini-Mental State Examination (MMSE) score. After EBT for 6 months, SBP/DBP in DTTH was 138.8±12.2/81.9±7.4 (ΔSBP-26±15.7; ΔDBP-11.4±9.8); PP was 57.0±10.8 (ΔPP-14.5±13.8) (all P<.001 vs baseline and non-DTTH group). A total of 2576 patients (87.4%) responded to EBT (ie, SBP <140 mm Hg and/or ΔSBP ≥15 mm Hg, or DBP <90 mm Hg and/or ΔDBP ≥10 mm Hg); 1426 DTTH patients (48.4%) achieved normalized SBP/DBP (ie, SBP <140 mm Hg and DBP <90 mm Hg). ΔPP in DTTH-isolated systolic hypertension (ISH) was -18.0±13.3 mm Hg (P=.003 vs DTTH-systolic-diastolic hypertension). End-of-EBT mean MMSE was 27.5±3.0 (P<.001 vs baseline). Blood pressure responses after EBT coincided with stabilization/improvement of MMSE in this retrospective investigation in DTTH patients. The average improvement in MMSE in DTTH patients was similar to that in non-DTTH patients. EBT effects on PP may be relevant to the evolution of MMSE in DTTH-ISH patients.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22277139      PMCID: PMC8108767          DOI: 10.1111/j.1751-7176.2011.00577.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  42 in total

1.  Metabolic syndrome and cognitive decline in French elders: the Three-City Study.

Authors:  C Raffaitin; C Féart; M Le Goff; H Amieva; C Helmer; T N Akbaraly; C Tzourio; H Gin; P Barberger-Gateau
Journal:  Neurology       Date:  2011-02-02       Impact factor: 9.910

Review 2.  Antihypertensive treatments, cognitive decline, and dementia.

Authors:  Emmanuelle Duron; Olivier Hanon
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease.

Authors:  C M Clark; L Sheppard; G G Fillenbaum; D Galasko; J C Morris; E Koss; R Mohs; A Heyman
Journal:  Arch Neurol       Date:  1999-07

4.  Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing.

Authors:  Vincenzo Solfrizzi; Emanuele Scafato; Cristiano Capurso; Alessia D'Introno; Anna Maria Colacicco; Vincenza Frisardi; Gianluigi Vendemiale; Marzia Baldereschi; Gaetano Crepaldi; Antonio Di Carlo; Lucia Galluzzo; Claudia Gandin; Domenico Inzitari; Stefania Maggi; Antonio Capurso; Francesco Panza
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-12-03       Impact factor: 10.154

5.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document.

Authors:  Giuseppe Mancia; Stéphane Laurent; Enrico Agabiti-Rosei; Ettore Ambrosioni; Michel Burnier; Mark J Caulfield; Renata Cifkova; Denis Clément; Antonio Coca; Anna Dominiczak; Serap Erdine; Robert Fagard; Csaba Farsang; Guido Grassi; Hermann Haller; Anthony Heagerty; Sverre E Kjeldsen; Wolfgang Kiowski; Jean Michel Mallion; Athanasios Manolis; Krzysztof Narkiewicz; Peter Nilsson; Michael H Olsen; Karl Heinz Rahn; Josep Redon; José Rodicio; Luis Ruilope; Roland E Schmieder; Harry A J Struijker-Boudier; Pieter A van Zwieten; Margus Viigimaa; Alberto Zanchetti
Journal:  J Hypertens       Date:  2009-11       Impact factor: 4.844

Review 6.  Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.

Authors:  Albert Fournier; Roxana Oprisiu-Fournier; Jean-Marie Serot; Olivier Godefroy; Jean-Michel Achard; Sebastien Faure; Hakim Mazouz; Mohamed Temmar; Adriana Albu; Régis Bordet; Olivier Hanon; François Gueyffier; Jiguang Wang; Sandra Black; Naoyuki Sato
Journal:  Expert Rev Neurother       Date:  2009-09       Impact factor: 4.618

7.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Circulation       Date:  2008-06-24       Impact factor: 29.690

8.  Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.

Authors:  Steven G Chrysant; Joel M Neutel; Keith C Ferdinand
Journal:  J Natl Med Assoc       Date:  2009-04       Impact factor: 1.798

9.  Blood pressure and brain injury in older adults: findings from a community-based autopsy study.

Authors:  Lucy Y Wang; Eric B Larson; Joshua A Sonnen; Jane B Shofer; Wayne McCormick; James D Bowen; Thomas J Montine; Ge Li
Journal:  J Am Geriatr Soc       Date:  2009-09-28       Impact factor: 5.562

Review 10.  Sympathetic neural mechanisms in human cardiovascular health and disease.

Authors:  Nisha Charkoudian; Jennifer A Rabbitts
Journal:  Mayo Clin Proc       Date:  2009-09       Impact factor: 7.616

View more
  5 in total

1.  TREATMENT RESPONSE IN ADULT PATIENTS WITH HYPERTENSION ATTENDING A SECONDARY HEALTH CARE CENTER IN SOUTH-WEST NIGERIA.

Authors:  I A Azeez; M D Dairo; J O Akinyemi
Journal:  Ann Ib Postgrad Med       Date:  2019-12

Review 2.  Do angiotensin receptor blockers protect against Alzheimer's disease?

Authors:  Hitomi Kurinami; Munehisa Shimamura; Naoyuki Sato; Hironori Nakagami; Ryuichi Morishita
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

Review 3.  Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors.

Authors:  Naoyuki Sato; Ryuichi Morishita
Journal:  Front Aging Neurosci       Date:  2013-11-05       Impact factor: 5.750

4.  Blood pressure and Purdue pegboard scores in individuals with hypertension after alternate nostril breathing, breath awareness, and no intervention.

Authors:  Shirley Telles; Arti Yadav; Nilima Kumar; Sachin Sharma; Naveen K Visweshwaraiah; Acharya Balkrishna
Journal:  Med Sci Monit       Date:  2013-01-21

Review 5.  Hypertension, brain damage and cognitive decline.

Authors:  Dariusz Gąsecki; Mariusz Kwarciany; Walenty Nyka; Krzysztof Narkiewicz
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.